750 Results for "

R-1

" in MedChemExpress (MCE) Product Catalog:
Products (750)

750 Results for "R-1" in MCE Product Catalog:

59
Raleukin
Raleukin
0 Images
59 Publications Verification
Cat. No.: HY-108841
CAS No.: 143090-92-0
Purity:  99.40%
Synonyms: Kineret; Anakinra

Target:  

Interleukin Related

Research Areas:  

Infection Inflammation/Immunology Cancer

Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction [1] .
loading...
    loading...
View All Sizes
53
Semaglutide
Semaglutide
0 Images
53 Cited Publications
Cat. No.: HY-114118
CAS No.: 910463-68-2
Purity:  99.84%
Target:  

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:  

Neurological Disease Metabolic Disease Cancer

Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [1] .
loading...
    loading...
View All Sizes
53
Semaglutide acetate
Semaglutide acetate
0 Images
53 Cited Publications
Cat. No.: HY-114118B
CAS No.: 1997361-85-9
Purity:  99.92%
Target:  

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:  

Neurological Disease Metabolic Disease Cancer

Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [1] .
loading...
    loading...
View All Sizes
53
Semaglutide TFA
Semaglutide TFA
0 Images
53 Cited Publications
Cat. No.: HY-114118A
Purity:  99.92%
Target:  

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:  

Neurological Disease Metabolic Disease Cancer

Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer [1] .
loading...
    loading...
View All Sizes
52
DL-Dithiothreitol
DL-Dithiothreitol
0 Images
52 Cited Publications
Cat. No.: HY-15917
CAS No.: 3483-12-3
Synonyms: DTT; rel-(2R,3R)-1,4-Dimercapto-2,3-butanediol
DL-Dithiothreitol (DTT) is a strong reductant with anti-disulfidptosis activity. When DL-Dithiothreitol is oxidized, it forms a stable six-membered ring with an internal disulfide bond [1] .
loading...
    loading...
View All Sizes
46
Exendin(9-39) amide
Exendin(9-39) amide
0 Images
46 Cited Publications
Cat. No.: HY-P0264
CAS No.: 133514-43-9
Synonyms: Avexitide
Target:  

GLP Receptor

Exendin (9-39) amide (Avexitide) is a competitive GLP-1R antagonist. Exendin (9-39) amide blocks the Semaglutide (HY-114118)-induced increase in insulin secretion and also attenuates the hypoglycemic effect of Semaglutide. Exendin (9-39) amide abolishes the islet-protective effect of Liraglutide. Exendin (9-39) amide can be used in research on type 2 diabetes and type 1 diabetes [1] .
loading...
    loading...
View All Sizes
46
Exendin(9-39) amide acetate
Exendin(9-39) amide acetate
0 Images
46 Cited Publications
Cat. No.: HY-P0264A
CAS No.: 2051593-46-3
Synonyms: Avexitide acetate
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease Inflammation/Immunology

Exendin (9-39) amide acetate (Avexitide acetate) is a competitive GLP-1R antagonist. Exendin (9-39) amide acetate blocks the Semaglutide (HY-114118)-induced increase in insulin secretion and also attenuates the hypoglycemic effect of Semaglutide. Exendin (9-39) amide acetate abolishes the islet-protective effect of Liraglutide. Exendin (9-39) amide acetate can be used in research on type 2 diabetes and type 1 diabetes [1] .
loading...
    loading...
View All Sizes
45
Sotuletinib hydrochloride
Sotuletinib hydrochloride
0 Images
45 Cited Publications
Cat. No.: HY-12768A
CAS No.: 2222138-31-8
Purity:  99.43%
Synonyms: BLZ945 hydrochloride
Target:  

c-Fms

Research Areas:  

Cancer

Sotuletinib (BLZ945) hydrochloride is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib hydrochloride can be used for microglia depletion, and for tumor and CNS-related disease research. [1].
loading...
    loading...
View All Sizes
45
Sotuletinib
Sotuletinib
0 Images
45 Cited Publications
Cat. No.: HY-12768
CAS No.: 953769-46-5
Purity:  99.83%
Synonyms: BLZ945
Target:  

c-Fms

Research Areas:  

Infection Neurological Disease Cancer

Sotuletinib (BLZ945) is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib can be used for microglia depletion, and for tumor and CNS-related disease research [1] .
loading...
    loading...
View All Sizes
43
Ceritinib
Ceritinib
0 Images
43 Cited Publications
Cat. No.: HY-15656
CAS No.: 1032900-25-6
Purity:  99.98%
Synonyms: LDK378
Target:  

Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R

Research Areas:  

Metabolic Disease Inflammation/Immunology Cancer

Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency [1] .
loading...
    loading...
View All Sizes
43
Ceritinib dihydrochloride
Ceritinib dihydrochloride
0 Images
43 Cited Publications
Cat. No.: HY-15656A
CAS No.: 1380575-43-8
Purity:  99.90%
Synonyms: LDK378 dihydrochloride
Target:  

Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R

Research Areas:  

Metabolic Disease Inflammation/Immunology Cancer

Ceritinib (LDK378) dihydrochloride is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib dihydrochloride also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib dihydrochloride shows great antitumor potency [1] .
loading...
    loading...
View All Sizes
36
Substance P TFA
Substance P TFA
0 Images
36 Cited Publications
Cat. No.: HY-P0201A
CAS No.: 148470-19-3
Synonyms: Neurokinin P TFA
Target:  

Neurokinin Receptor Endogenous Metabolite

Research Areas:  

Neurological Disease Metabolic Disease Cancer

Substance P TFA (Neurokinin P TFA) is a CNS-penetrant neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R) .
loading...
    loading...
View All Sizes
32
Picropodophyllin
Picropodophyllin
0 Images
32 Cited Publications
Cat. No.: HY-15494
CAS No.: 477-47-4
Purity:  99.85%
Synonyms: AXL1717; Picropodophyllotoxin; PPP
Category:  

Lignans 500 - Internal Server Error | MedChemExpress

Oops!

Sorry, Something went wrong on our server.
Our team has been notified and is working to fix the issue.